Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Lineage Cell Therapeutics's enterprise value was $228.78M on Nov 11, 2026, against $363.65M a year earlier. Over the last 5 years it ranged from $49.80M to $409.81M, with a median of $178.59M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $228.78M | -33.3% |
| 2025 | Dec 31, 2025 | $342.92M | +464.1% |
| 2024 | Dec 31, 2024 | $60.79M | -58.9% |
| 2023 | Dec 29, 2023 | $147.95M | +12.9% |
| 2022 | Dec 30, 2022 | $131.02M | -62.2% |
| 2021 | Dec 31, 2021 | $346.52M | +54.1% |
| 2020 | Dec 31, 2020 | $224.90M | +134.3% |
| 2019 | Dec 31, 2019 | $95.98M | +3.4% |
| 2018 | Dec 31, 2018 | $92.84M | -61.8% |
| 2017 | Dec 29, 2017 | $243.06M | -32.0% |
| 2016 | Dec 30, 2016 | $357.58M | +0.7% |
| 2015 | Dec 31, 2015 | $355.17M | +29.0% |
| 2014 | Dec 31, 2014 | $275.33M | +33.7% |
| 2013 | Dec 31, 2013 | $205.95M | +29.7% |
| 2012 | Dec 31, 2012 | $158.81M | -41.5% |
| 2011 | Dec 30, 2011 | $271.47M | – |
See a number that looks wrong?